Skip to main content

Table 2 Clinical trials HDAC inhibitors used as single agents

From: Histone deacetylase inhibitors: clinical implications for hematological malignancies

Drug Study Phase Disease NCT Status
Vorinostat (SAHA) A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia II PV NCT00866762 R
Vorinostat (SAHA) Study of Vorinostat (MK0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL) Patients II FL_indolent NHL MCL NCT00875056 ANR
Vorinostat (SAHA) MK0683 Phase I Study in CTCL Patients I CTCL NCT00771472 ANR
Vorinostat (SAHA) Phase IIa Vorinostat (MK0683, SAHA) Study in Lower Risk Myelodysplastic Syndromes II MDS NCT00486720 C
Vorinostat (SAHA) A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma I Lymphoma NCT00127140 ANR
Vorinostat (SAHA) Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma III CTCL NCT00419367 ANR
Vorinostat (SAHA) An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma II DLBCL NCT00097929 C
Vorinostat (SAHA) Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma II CTCL NCT00091559 C
Vorinostat (SAHA) A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma I MM NCT00109109 C
Vorinostat (SAHA) Vorinostat in Treating Patients With Acute Myeloid Leukemia II AML MDS NCT00305773 C
Vorinostat (SAHA) A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia II PV and ET NCT00866762 R
CHR-2845 Safety and Tolerability of CHR-2845 to Treat Hematological Diseases or Lymphoid Malignancies (CHR-2845-001) I Lymphoid Malignancies NCT00820508 R
Pivanex A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia II CLL, SLL NCT00083473 C
Resminostat (4SC-201) Resminostat (4SC-201) in Relapsed or Refractory Hodgkin’s Lymphoma (SAPHIRE) II HD NCT01037478 R
Panobinostat (LBH 589) Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma II CTCL, T-ALL NCT00699296 C
Panobinostat (LBH 589) A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies I - II Lymphoma Leukemia MM NCT00621244 A N R
Panobinostat (LBH 589) Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma II - III PTCL; CTCL NCT00490776 C
Panobinostat (LBH 589) Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia II Leukemia NCT00723203 R
Panobinostat (LBH 589) Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia II ALL; AML NCT00723203 R
Panobinostat (LBH 589) Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis II MMM NCT00931762 R
Panobinostat (LBH 589) A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin’s Lymphoma III HL NCT01034163 ANR
Panobinostat (LBH 589) Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkin’s Lymphom II HL NCT00742027 ANR
Panobinostat (LBH 589) Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia II ALL NCT00723203 R
Panobinostat (LBH 589) Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma II - III CTCL NCT00425555 ANR
Panobinostat (LBH 589) Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis) II - III CML NCT00449761 C
Panobinostat (LBH 589) Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma II CTCL NCT00699296 C
Panobinostat (LBH 589) LBH589 in Relapsed or Relapsed and Refractory Waldenstrom’s Macroglobulinemia II WM NCT00936611 R
Panobinostat (LBH 589) Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase II - III CML NCT00451035 C
Panobinostat (LBH 589) Oral LBH589 in Relapsed or Refractory CLL and MCL II CML CLL NCT01090973 R
Panobinostat (LBH 589) Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma II - III CTCL NCT00490776 C
Belinostat (PXD101) Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) II PTCL NCT00865969 R
Belinostat (PXD101) Clinical Trial of PXD101 in Patients With T-Cell Lymphomas II CTCL; PTCL; HD NCT00274651 A N R
Belinostat (PXD101) PXD101 in Treating Patients With Myelodysplastic Syndromes II MDS NCT00357162 R
Belinostat (PXD101)) Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) II PTCL NCT01016990 R
Givinostat (ITF2357) Phase II High Pulse Dose Clinical Trial of Orally Administered ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma II MM NCT00792506 ANR
Givinostat (ITF2357) Ph II Study of an HDAC Inhibitor in Very High-Risk Relapsed/Refractory Hodgkin’s Lymphoma Patients I - II HD NCT00496431 R
Givinostat (ITF2357) Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases II MPD (JAK2-V617F +) NCT00606307 C
Givinostat (ITF2357) Phase II Study of Histone-Deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia II CLL NCT00792831 C
Givinostat (ITF2357) Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera (PV) II PV NCT00928707 R
Romidepsin (FK228) FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma II Lymphoma NCT00077194 C
Romidepsin (FK228) FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma II Lymphoma NCT00383565 ANR
Romidepsin (FK228) A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma II CTCL NCT00106431 C
Romidepsin (FK228) A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma II PTCL NCT00426764 ANR
Romidepsin (FK228) Topical Romidepsin in Treating Patients With Stage I or Stage II Cutaneous T-Cell Non-Hodgkin’s Lymphoma I CTCL NCT00477698 R
Romidepsin (FK228) FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma II MM NCT00066638 ANR
Romidepsin (FK228) FR901228 in Treating Patients With Hematologic Cancer I Leukemia   
Lymphoma NCT00024180 C    
Romidepsin (FK228) FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin’s Lymphoma II AML,ALL,MDS,MM,MPN NCT00042822 C
Romidepsin (FK228) FR901228 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia II AML NCT00062075 ANR
JNJ-26481585 A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced of Refractory Leukemia or Myelodysplastic Syndrome. I AML, ALL; CML; MDS;B-CLL NCT00676728 R
Mocetinostat (MGCD0103) A Phase I Study of MGCD0103 Given Three Times Weekly In Patients With Leukemia Or Myelodysplastic Syndrome I AML MDS NCT00324129 C
Mocetinostat (MGCD0103) A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes I AML MDS NCT00324194 C
Mocetinostat (MGCD0103) A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia I II MDS AML NCT00324220 C
Mocetinostat (MGCD0103) MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease II MDS AML NCT00374296 C
Mocetinostat (MGCD0103) Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma II HL NHL NCT00359086 C
Mocetinostat (MGCD0103) MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease II MDS AML NCT00374296 C
Mocetinostat (MGCD0103) Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma II NHL HL NCT00359086 ANR
Mocetinostat (MGCD0103) A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia II CLL NCT00431873 C
Mocetinostat (MGCD0103) Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin’s Lymphoma II HL NCT00358982 C
Entinostat (MS 275) MS-275 in Treating Patients With Hematologic Cancer I Hematological cancers NCT00015925 C
Entinostat (MS 275) A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin’s Lymphoma II HL NCT00866333 R
  1. R recruiting, C completed, ANR active, not recruiting; MDS myelodysplastic syndromes, AML acute myelogenous leukemia, T/B-ALL acute lymphoblastic leukemia (T- or B-cell), HD Hodgkin disease, NHL non-Hodgkin lymphoma, DLBL diffuse large B-cell lymphoma, FL follicular lymphoma, CTCL cutaneous T-cell lymphoma, CLL chronic lymphocytic leukemia, SLL small lymphocyte lymphoma, MCL mantle cell lymphoma, PTCL peripheral T-cell lymphoma, CML chronic myelogenous leukemia, MPN myeloproliferative neoplasm, WM Waldenstrom macroglobulinemia, MM multiple myeloma, PV policytemia vera, ET essential thombocytemia, MMM myelofibrosis with myeloid metaplasia